Infinity Pharmaceuticals (INFI) Stock Forecast, Price Target & Predictions
INFI Stock Forecast
Infinity Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
INFI Analyst Ratings
According to 3 Wall Street analysts, Infinity Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for INFI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 16, 2022 | B. Riley Securities | - | Neutral | Downgrade |
| May 23, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 28, 2021 | Wells Fargo | - | Overweight | Upgrade |
Infinity Pharmaceuticals's last stock rating was published by B. Riley Securities on Nov 16, 2022. The company Downgrade its INFI rating from "null" to "Neutral".
Infinity Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
| ADTX | Aditxt | $0.45 | $160.00 | 35455.56% | - |
| INFI | Infinity Pharmaceuticals | $0.01 | $3.00 | 29900.00% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| CTMX | CytomX Therapeutics | $1.21 | $5.77 | 376.86% | Buy |
| TRVI | Trevi Therapeutics | $3.33 | $12.00 | 260.36% | Buy |
| DRMA | Dermata Therapeutics | $2.06 | $6.00 | 191.26% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| NUVB | Nuvation Bio | $3.07 | $6.75 | 119.87% | Buy |
| NXTC | NextCure | $1.38 | $3.00 | 117.39% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CCCC | C4 Therapeutics | $6.46 | $11.33 | 75.39% | Hold |
| TIL | Instil Bio | $64.79 | $78.25 | 20.77% | Hold |
INFI Forecast FAQ
Is Infinity Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Infinity Pharmaceuticals (INFI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of INFI's total ratings.